Phaseline

Targets › RPODC

RPODC: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 3; Immunology; next expected readout Jun 2030.

Open in Phaseline: the race on RPODC, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
McGill University Health Centre/Research Institute of the McGill University Health CentreFidaxomicin
DNA-directed RNA polymerase inhibitor
RPODCPhase 3Clostridia Difficile ColitisJun 2030

Conditions

Clostridia Difficile Colitis (1)

Modalities

small molecule (1)

Companies

McGill University Health Centre/Research Institute of the McGill University Health Centre (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.